pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

6,533 catalysts · 3,603 8k filing · 1,000 device adverse event · 773 grant · 578 earnings · 220 approval · 172 phase 2 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2026-03-31×clear all
type
  • 8k filing3,603
  • device adverse event1,000
  • grant773
  • earnings578
  • approval220
  • phase 2 completion172
device 510k
135
  • drug shortage133
  • device pma77
  • phase 1 completion73
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 20, 2026

    50
    ›Apr 25, 2026phase 2 completion127d agoTehran University of Medical Sciences — FOLFOX [leucovorin + fluorouracil + oxaliplatin] (Phase II Trial Completion)FOLFOX [leucovorin + fluorouracil + oxaliplatin]

    Therapy area: Oncology. Indication: Rectal Cancer

    full page →FOLFOX [leucovorin + fluorouracil + oxaliplatin] →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoNational Institute of Siddha — undisclosed siddha medicine (Phase II Trial Completion)undisclosed siddha medicine

    Therapy area: Respiratory. Indication: Asthma

    full page →undisclosed siddha medicine →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

    Therapy area: Infectious Disease. Indication: Dental Abscess

    full page →Gengigel →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoJawaharlal Nehru Medical College Ajmer — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)blinatumomab

    Therapy area: Oncology. Indication: B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

    full page →blinatumomab →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoNizam's Institute of Medical Sciences — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Genito Urinary System. Indication: Post-Operative Pain, Renal Stones/Calculi

    full page →dexamethasone →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoEmami Ltd — Himani fast relief gel (Phase II Trial Completion)Himani fast relief gel

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders. Indication: Inflammation, Myalgia (Muscle Pain), Unspecified Musculoskeletal Disorders

    full page →Himani fast relief gel →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoJawaharlal Nehru Medical College — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Other Diseases. Indication: Injury, Post-Operative Pain

    full page →dexmedetomidine →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoSeoul National University — onabotulinumtoxin A (Phase II Trial Completion)onabotulinumtoxin A

    Therapy area: Central Nervous System. Indication: Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy)

    full page →onabotulinumtoxin A →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoNational Taiwan University Hospital — levocarnitine (Phase II Trial Completion)Carnitor

    Therapy area: Gastrointestinal. Indication: Unspecified Gastrointestinal Disorders

    full page →Carnitor →source: globaldata
    ›Apr 25, 2026phase 2 completion127d agoFuzhou Second General Hospital — butorphanol (Phase II Trial Completion)butorphanol

    Therapy area: Musculoskeletal Disorders. Indication: Unspecified Musculoskeletal Disorders

    full page →butorphanol →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoNovo Nordisk AS — zalfermin (Phase II Trial Initiation)zalfermin

    Therapy area: Gastrointestinal. Indication: Liver Failure (Hepatic Insufficiency)

    full page →zalfermin →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoCoorg Instituite of Dental Sciences — chlorhexidine (Phase II Trial Initiation)chlorhexidine

    Therapy area: Mouth and Dental Disorders. Indication: Periodontitis

    full page →chlorhexidine →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoAffiliated Renhe Hospital of China Three Gorges University — platelet rich plasma (Phase II Trial Initiation)platelet rich plasma

    Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

    full page →platelet rich plasma →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoAffiliated Hospital of North Sichuan Medical College — Radioactive Iodine Therapy (Phase II Trial Initiation)Radioactive Iodine Therapy

    Therapy area: Oncology. Indication: Follicular Thyroid Cancer, Papillary Thyroid Cancer, Thyroid Cancer

    full page →Radioactive Iodine Therapy →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoGSK plc — dostarlimab (Phase II Trial Initiation)dostarlimab

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →dostarlimab →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoKIMS Hospital — bifidobacterium (Phase II Trial Initiation)bifidobacterium

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →bifidobacterium →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoShanghai Mental Health Center — undisclosed drug (Phase II Trial Initiation)undisclosed drug

    Therapy area: Central Nervous System. Indication: Anxiety Disorders

    full page →undisclosed drug →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoCentenario Hospital Miguel Hidalgo — symbiotic (Phase II Trial Initiation)symbiotic

    Therapy area: Genito Urinary System. Indication: Chronic Kidney Disease (Chronic Renal Failure)

    full page →symbiotic →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoGaziantep City Hospital — dexamethasone (Phase II Trial Initiation)dexamethasone

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoShanghai Henlius Biotech Inc — HLX-43 (Phase II Trial Initiation)HLX-43

    Therapy area: Oncology. Indication: Breast Cancer, Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

    full page →HLX-43 →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoJazz Pharmaceuticals Plc — durvalumab (Phase II Trial Initiation)durvalumab

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →durvalumab →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoGlenmark Pharmaceuticals Ltd — (clascoterone + latanoprost) (Phase II Trial Initiation)(clascoterone + latanoprost)

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →(clascoterone + latanoprost) →source: globaldata
    ›Apr 25, 2026phase 2 initiation127d agoNovartis AG — asciminib hydrochloride (Phase II Trial Initiation)asciminib hydrochloride

    Therapy area: Oncology. Indication: Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

    full page →asciminib hydrochloride →source: globaldata
    ›Apr 25, 2026phase 3 completion127d agoMashhad University of Medical Sciences — acetazolamide (Phase III Trial Completion)ACETAZOLAMIDE

    Therapy area: Central Nervous System. Indication: Epilepsy

    full page →ACETAZOLAMIDE →source: globaldata
    ›Apr 25, 2026phase 3 completion127d agoAin Shams University — lidocaine (Phase III Trial Completion)LIDOCAINE

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →LIDOCAINE →source: globaldata
    ›Apr 25, 2026phase 3 initiation127d agoOTCPharm — OTC-BSR-0125 (Phase III Trial Initiation)OTC-BSR-0125

    Therapy area: Gastrointestinal. Indication: Anal Fissure, Hemorrhoids

    full page →OTC-BSR-0125 →source: globaldata
    ›Apr 25, 2026phase 3 initiation127d agoSwami Dayanand Hospital — levobupivacaine (Phase III Trial Initiation)levobupivacaine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Inguinal Hernia, Post-Operative Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 25, 2026phase 3 initiation127d agoDr. Reddy's Laboratories Ltd — olokizumab (Phase III Trial Initiation)olokizumab

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →olokizumab →source: globaldata
    ›Apr 25, 2026phase iii iv trial completion127d agoParul Institute of Homoeopathy And Research — ferrum phosphoricum (Phase III/IV Trial Completion)ferrum phosphoricum

    Therapy area: Hematological Disorders. Indication: Iron Deficiency Anemia

    full page →ferrum phosphoricum →source: globaldata
    ›Apr 25, 2026phase iv trial initiation127d agoChristian Medical College Vellore — ketorolac (Phase IV Trial Initiation)ketorolac

    Therapy area: Central Nervous System, Genito Urinary System. Indication: Pain, Renal Colic, Renal Stones/Calculi

    full page →ketorolac →source: globaldata
    ›Apr 25, 2026phase iv trial initiation127d agoIstinye University — undisclosed general anesthesia (Phase IV Trial Initiation)undisclosed general anesthesia

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →undisclosed general anesthesia →source: globaldata
    ›Apr 26, 2026constraining patent expiry europe126d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Europe))BB-101

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →BB-101 →source: globaldata
    ›Apr 26, 2026patent expiry126d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Japan))BB-101

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →BB-101 →source: globaldata
    ›Apr 26, 2026phase 1 completion126d agoPfizer Inc — PF-08046032 (Phase I Trial Completion)PF-08046032

    Therapy area: Oncology. Indication: Advanced Malignancy, Diffuse Large B-Cell Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Solid Tumor

    full page →PF-08046032 →source: globaldata
    ›Apr 26, 2026phase 1 completion126d agoMicillic Ltd — Ubisol-Q10 (Phase I Trial Completion)Ubisol-Q10

    Therapy area: Undisclosed. Indication: Unspecified

    full page →Ubisol-Q10 →source: globaldata
    ›Apr 26, 2026phase 1 2 completion126d agoKing George's Medical University — ropivacaine (Phase I/II Trial Completion)ropivacaine ER

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →ropivacaine ER →source: globaldata
    ›Apr 26, 2026phase 1 2 completion126d agoMahatma Gandhi Ayurved College Hospital and research centre — ayurvedic medicine (Phase I/II Trial Completion)ayurvedic medicine

    Therapy area: Cardiovascular. Indication: Thrombophlebitis

    full page →ayurvedic medicine →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoUniversity Health Network — decidual stromal cells (Phase II Trial Completion)decidual stromal cells

    Therapy area: Immunology. Indication: Graft Versus Host Disease (GVHD)

    full page →decidual stromal cells →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoCentral Council for Research in Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Ophthalmology. Indication: Asthenopia (Eye Strain), Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

    full page →unani medicine →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoBanaras Hindu University — oxytocin (Phase II Trial Completion)Oxytocin Hikma

    Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

    full page →Oxytocin Hikma →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoAnyang Tumor Hospital — camrelizumab (Phase II Trial Completion)apatinib mesylate

    Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

    full page →apatinib mesylate →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoChongqing Jinsaixing Medical Technology Co Ltd — Neauvia Intense (Phase II Trial Completion)Neauvia Intense

    Therapy area: Dermatology. Indication: Wrinkles

    full page →Neauvia Intense →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoAll India Institute of Medical Sciences Bibinagar — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Post-Operative Pain, Umbilical Hernia

    full page →dexmedetomidine →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoClostraBio Inc — CLB-101 (Phase II Trial Completion)CLB-101

    Therapy area: Gastrointestinal, Metabolic Disorders. Indication: Obesity, Overweight, Unspecified Gastrointestinal Disorders

    full page →CLB-101 →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

    full page →bupivacaine →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoWinSanTor Inc — pirenzepine (Phase II Trial Completion)pirenzepine

    Therapy area: Toxicology. Indication: Chemotherapy Induced Peripheral Neuropathy

    full page →pirenzepine →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoMemorial Sloan Kettering Cancer Center — iberdomide hydrochloride (Phase II Trial Completion)iberdomide hydrochloride

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease)

    full page →iberdomide hydrochloride →source: globaldata
    ›Apr 26, 2026phase 2 completion126d agoBharati Vidyapeeth Deemed University — cinnamon (Phase II Trial Completion)cinnamon

    Therapy area: Metabolic Disorders. Indication: Glucose Intolerance

    full page →cinnamon →source: globaldata
    ›Apr 26, 2026phase 2 initiation126d agoBeijing Chao-Yang Hospital — oxymetazoline hydrochloride (Phase II Trial Initiation)oxymetazoline hydrochloride

    Therapy area: Ophthalmology. Indication: Blepharitis, Ptosis

    full page →oxymetazoline hydrochloride →source: globaldata
    ← prev
    page 51 of 131
    next →
    $GSK50.27-2.26%
    $NVS153.81-0.54%
    $JAZZ244.54-2.61%
    $PFE27.96-0.21%